Osborn Rohs Williams & Donohoe Ltd maintained its stake in Celgene Corp. (NASDAQ:CELG) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,380 shares of the biopharmaceutical company’s stock at the end of the third quarter. Osborn Rohs Williams & Donohoe Ltd’s holdings in Celgene Corp. were worth $2,444,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Ngam Advisors L.P. increased its stake in Celgene Corp. by 3.6% in the second quarter. Ngam Advisors L.P. now owns 166,196 shares of the biopharmaceutical company’s stock valued at $16,392,000 after buying an additional 5,707 shares in the last quarter. Atwood & Palmer Inc. increased its stake in Celgene Corp. by 1.7% in the second quarter. Atwood & Palmer Inc. now owns 156,343 shares of the biopharmaceutical company’s stock valued at $15,420,000 after buying an additional 2,543 shares in the last quarter. Fisher Asset Management LLC increased its stake in Celgene Corp. by 3.0% in the second quarter. Fisher Asset Management LLC now owns 204,128 shares of the biopharmaceutical company’s stock valued at $21,109,000 after buying an additional 5,968 shares in the last quarter. Putnam FL Investment Management Co. increased its stake in Celgene Corp. by 1.4% in the second quarter. Putnam FL Investment Management Co. now owns 117,359 shares of the biopharmaceutical company’s stock valued at $11,575,000 after buying an additional 1,575 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its stake in Celgene Corp. by 0.8% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,488,765 shares of the biopharmaceutical company’s stock valued at $245,467,000 after buying an additional 20,006 shares in the last quarter. 76.43% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Celgene Corp. (NASDAQ:CELG)

Shares of Celgene Corp. (NASDAQ:CELG) traded down 2.96% during trading on Wednesday, reaching $118.51. 5,514,032 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $108.88 and a 200-day moving average price of $106.73. Celgene Corp. has a 52-week low of $93.05 and a 52-week high of $127.00. The company has a market capitalization of $91.87 billion, a PE ratio of 45.01 and a beta of 1.71.

Celgene Corp. (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.48 by $0.10. Celgene Corp. had a net margin of 19.71% and a return on equity of 70.48%. The business earned $2.98 billion during the quarter, compared to analyst estimates of $2.84 billion. During the same quarter in the previous year, the business earned $1.23 EPS. Celgene Corp.’s quarterly revenue was up 27.8% compared to the same quarter last year. On average, equities analysts forecast that Celgene Corp. will post $5.92 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was reported by Financial Market News and is the propert of of Financial Market News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this piece can be viewed at http://www.financial-market-news.com/celgene-corp-celg-position-maintained-by-osborn-rohs-williams-donohoe-ltd/1211317/.

CELG has been the subject of several analyst reports. Robert W. Baird reaffirmed an “outperform” rating and set a $162.00 price objective on shares of Celgene Corp. in a research note on Tuesday, September 13th. BMO Capital Markets reiterated an “outperform” rating and set a $141.00 target price on shares of Celgene Corp. in a research report on Tuesday, August 23rd. Vetr cut Celgene Corp. from a “strong-buy” rating to a “buy” rating and set a $115.50 target price on the stock. in a research report on Monday, October 31st. Citigroup Inc. boosted their target price on Celgene Corp. from $124.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, September 29th. Finally, Cowen and Company reiterated an “outperform” rating and set a $150.00 target price on shares of Celgene Corp. in a research report on Thursday, August 25th. Four investment analysts have rated the stock with a hold rating and twenty-seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $136.77.

In other Celgene Corp. news, Director Gilla Kaplan sold 9,710 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $106.44, for a total transaction of $1,033,532.40. Following the completion of the transaction, the director now owns 72,142 shares of the company’s stock, valued at approximately $7,678,794.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Corp /De/ Celgene bought 800,150 shares of the business’s stock in a transaction on Monday, October 24th. The shares were purchased at an average cost of $14.00 per share, with a total value of $11,202,100.00. The disclosure for this purchase can be found here. 0.97% of the stock is currently owned by corporate insiders.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corp. (NASDAQ:CELG).

Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with MarketBeat.com's FREE daily email newsletter.